PUBLISHER: The Business Research Company | PRODUCT CODE: 1760704
PUBLISHER: The Business Research Company | PRODUCT CODE: 1760704
Prurigo nodularis treatment involves various medical approaches aimed at relieving the persistent itching and skin lesions associated with this inflammatory condition. The primary goal is to break the cycle of scratching that worsens the symptoms. Treatment focuses on soothing itching, promoting the healing of nodules, and improving the overall well-being of the patient.
The main types of prurigo nodularis treatment include medications, cryotherapy, phototherapy, pulsed dye laser, and other therapies. Medications are used to alleviate itching, reduce inflammation, and modulate the immune response. Diagnosis typically involves skin biopsies, blood tests, and other methods. Treatments are administered through various routes, including topical, oral, and parenteral administration. These treatments are distributed through multiple channels, such as hospital pharmacies, retail pharmacies, and online pharmacies, and are used by different end-users, including clinics, hospitals, and others.
The prurigo nodularis treatment market research report is one of a series of new reports from The Business Research Company that provides prurigo nodularis treatment market statistics, including the prurigo nodularis treatment industry global market size, regional shares, competitors with the prurigo nodularis treatment market share, detailed prurigo nodularis treatment market segments, market trends, and opportunities, and any further data you may need to thrive in the prurigo nodularis treatment industry. This prurigo nodularis treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The prurigo nodularis treatment market size has grown strongly in recent years. It will grow from $1.64 billion in 2024 to $1.73 billion in 2025 at a compound annual growth rate (CAGR) of 5.4%. The growth during the historic period can be attributed to increased investment in dermatology research, a rising demand for personalized medicine, a growing pipeline of novel therapies, more regulatory approvals for treatment options, and an increased use of teledermatology services.
The prurigo nodularis treatment market size is expected to see strong growth in the next few years. It will grow to $2.11 billion in 2029 at a compound annual growth rate (CAGR) of 5.1%. The growth during the forecast period can be attributed to increasing healthcare expenditure, rising awareness of prurigo nodularis, a growing demand for targeted therapies, an increase in research and development activities, and more approvals of novel treatments. Key trends in the forecast period include advancements in biologic therapies, improved diagnostic approaches for skin conditions, innovations in topical treatment formulations, integration of teledermatology services, and the development of advanced patient-centric care models.
The increasing prevalence of chronic skin conditions is expected to drive the growth of the prurigo nodularis treatment market in the coming years. Chronic skin conditions are long-term or recurring skin disorders that often require ongoing management and can significantly impact a person's quality of life. The rise in these conditions is attributed to higher exposure to environmental pollutants, which can damage the skin's natural barrier and cause persistent inflammation. Prurigo nodularis treatments focus on addressing the underlying causes of chronic skin conditions by targeting inflammatory pathways responsible for ongoing itching and skin lesions. By regulating immune system overactivity, these therapies effectively alleviate symptoms and improve quality of life for patients with prurigo nodularis. For example, in July 2023, the Office of Health Economics (OHE), a UK-based charity, reported that hidradenitis suppurativa (HS), a painful chronic skin disease, affects at least 200,000 people in the UK, with an estimated economic impact of £3.83 billion ($4.35 billion) annually. Therefore, the increasing incidence of chronic skin conditions is contributing to the growth of the prurigo nodularis treatment market.
Leading companies in the prurigo nodularis treatment market are concentrating on developing innovative therapies, including monoclonal antibodies, which aim to target specific immune pathways and offer more effective symptom relief. Monoclonal antibodies are synthetic molecules designed to replicate the immune system's natural ability to combat harmful pathogens including viruses. For example, in August 2024, the Switzerland-based pharmaceutical company Galderma announced that the U.S. Food and Drug Administration (FDA) had approved Nemluvio (nemolizumab) for the treatment of adult patients with prurigo nodularis. This approval followed promising results from the OLYMPIA clinical trials, in which Nemluvio showed notable improvements in itch intensity and skin nodules. The treatment specifically targets IL-31 signaling, which plays a crucial role in driving the symptoms of prurigo nodularis.
In December 2022, MyHealthTeam, a U.S.-based provider of treatment solutions for prurigo nodularis, teamed up with Arcutis Biotherapeutics to introduce MySebDermTeam, a new social platform designed to support individuals living with seborrheic dermatitis. The partnership aims to tackle issues including underdiagnosis and limited access to reliable information, particularly within underserved communities, by providing trusted connections and expert advice to help speed up diagnosis and treatment. Arcutis Biotherapeutics is a US-based biopharmaceutical company focused on developing and commercializing therapies for dermatological conditions.
Major players in the prurigo nodularis treatment market are Roche Holding AG, Sanofi S.A., Amgen Inc., Regeneron Pharmaceuticals Inc., Galderma S.A., Incyte Corporation, LEO Pharma A/S, Almirall S.A., Maruho Co. Ltd., VYNE Therapeutics Inc., Kiniksa Pharmaceuticals Ltd., Trevi Therapeutics Inc., Healio, Keymed Biosciences Inc., MyHealthTeam, Shanghai SIGMA High-tech Co. Ltd., Celgene Corporation, Dermatology Treatment and Research Center, Hightower Clinical, Celldex Therapeutics Inc., Psoriasis Treatment Center of Central New Jersey, and Skin Care Research.
North America was the largest region in the prurigo nodularis treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in prurigo nodularis treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the prurigo nodularis treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The prurigo nodularis treatment market consists of revenues earned by entities by providing services such as medical consultation, psychological support, wound care, and bandaging. The market value includes the value of related goods sold by the service provider or included within the service offering. The prurigo nodularis treatment market also includes sales of patch test kits, punch biopsy tools, and injectable monoclonal antibodies. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Prurigo Nodularis Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on prurigo nodularis treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for prurigo nodularis treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The prurigo nodularis treatment market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.